Dashboard
1
With a fall in Operating Profit of -28.31%, the company declared Very Negative results in Mar 25
- The company has declared negative results for the last 2 consecutive quarters
- INTEREST(HY) At CNY 7.78 MM has Grown at 27%
- OPERATING CASH FLOW(Y) Lowest at CNY 87.38 MM
- ROCE(HY) Lowest at 16.7%
2
With ROE of 16.66%, it has a expensive valuation with a 3.52 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,206 Million (Small Cap)
21.00
NA
2.67%
0.40
16.66%
3.52
Revenue and Profits:
Net Sales:
289 Million
(Quarterly Results - Jun 2025)
Net Profit:
43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.84%
0%
-4.84%
6 Months
-1.46%
0%
-1.46%
1 Year
-14.65%
0%
-14.65%
2 Years
-36.89%
0%
-36.89%
3 Years
-30.32%
0%
-30.32%
4 Years
-11.93%
0%
-11.93%
5 Years
-49.73%
0%
-49.73%
GuiZhou SanLi Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.59%
EBIT Growth (5y)
13.17%
EBIT to Interest (avg)
29.90
Debt to EBITDA (avg)
0.18
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.88
Tax Ratio
13.06%
Dividend Payout Ratio
49.87%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.56%
ROE (avg)
15.30%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
3.52
EV to EBIT
21.75
EV to EBITDA
16.93
EV to Capital Employed
2.80
EV to Sales
3.05
PEG Ratio
NA
Dividend Yield
2.67%
ROCE (Latest)
12.89%
ROE (Latest)
16.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
289.40
492.50
-41.24%
Operating Profit (PBDIT) excl Other Income
59.10
87.80
-32.69%
Interest
3.50
4.50
-22.22%
Exceptional Items
0.10
0.00
Consolidate Net Profit
42.90
61.60
-30.36%
Operating Profit Margin (Excl OI)
138.50%
139.50%
-0.10%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -41.24% vs 76.27% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -30.36% vs 31.62% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,117.10
1,618.40
30.81%
Operating Profit (PBDIT) excl Other Income
400.50
307.00
30.46%
Interest
14.60
4.20
247.62%
Exceptional Items
0.10
-0.00
Consolidate Net Profit
279.80
294.90
-5.12%
Operating Profit Margin (Excl OI)
153.30%
166.50%
-1.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 30.81% vs 35.97% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -5.12% vs 53.67% in Dec 2023
About GuiZhou SanLi Pharmaceutical Co., Ltd. 
GuiZhou SanLi Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






